Abstract
Bone is the most common site of metastasis for breast cancer. Bone metastasis significantly affects both quality of life and survival of the breast cancer patient. Clinically, complications secondary to bone metastasis include pain, pathologic fractures, spinal cord compression, and hypercalcemia of malignancy. Because bone metastasis is extremely common in patients with metastatic breast cancer, clinical management of bone metastases is an important and challenging aspect of treatment in the metastatic setting. The skeleton is a metabolically active organ system that undergoes continuous remodeling throughout life. A delicate balance of the bone-forming osteoblasts and bone-resorbing osteoclasts in the dynamic microenvironment of the skeleton maintains normal bone remodeling and integrity. The presence of metastatic lesions in bone disrupts the normal bone microenvironment and upsets the fine balance between the key components. The changes in the bone microenvironment then create a vicious cycle that further promotes bone destruction and tumor progression. Various therapeutic options are available for bone metastases of breast cancer, and treatment can be tailored for each patient and, often requires multiple therapeutic interventions. Commonly used modalities include local therapies such as surgery, radiation therapy and radiofrequency ablation (RFA) together with systemic therapies such as endocrine therapy, chemotherapy, monoclonal antibody-based therapy, bone-enhancing therapy and radioisotope therapy. Despite the use of various therapeutic modalities, bone metastases eventually become resistant to therapy, and disease progresses. In this chapter, we describe the clinical picture and biological mechanism of bone metastases in breast cancer. We also discuss known risk factors as well as detection and assessment of bone metastases. We present therapeutic options for bone metastasis using a multidisciplinary approach. Further, we describe future directions for bone metastasis management, focusing on novel bone-specific targeted therapies.
An erratum to this chapter is available at doi:10.1007/978-1-4614-5647-6_23
An erratum to this chapter can be found at http://dx.doi.org/10.1007/978-1-4614-5647-6_23
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2):6243s–6249s
Gainford MC, Dranitsaris G, Clemons M (2005) Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 330(7494):769–773
Scheid V, Buzdar AU, Smith TL et al (1986) Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 58:2589–2593
Plunkett TA, Smith P, Rubens RD (2000) Risk of complications from bone metastases in breast cancer: implications for management. Eur J Cancer 36:476–482
Domchek SM, Younger J, Finkelstein DM et al (2000) Predictors of skeletal complications complications in patients with metastatic breast carcinoma. Cancer 89:363–368
Sathiakumar N, Delzell E, Morrisey MA et al (2012) Mortality following bone metastasis and skeletal-related events among women with breast cancer: A population-based analysis of US Medicare beneficiaries. Breast Cancer Res Treat 131(1):231–238
Leone BA, Romero A, Rabinovich MG et al (1988) Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis, The GOCS (Grupo Oncológico Cooperativo del Sur) experience. Am J Clin Oncol 11(6):618–622
James JJ, Evans AJ, Pinder SE et al. (2003) Bone metastases from breast carcinoma: histopathological—radiological correlations and prognostic features. Br J Cancer 18;89(4):660–665
Colleoni M, O’Neill A, Goldhirsch A et al (2000) Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 18(23):3925–3935
Lousquy R, Delpech Y, Rouzier R (2011) Nomogram to predict bone metastasis in patients with non metastatic breast cancer. Poster presentation at San Antonio breast cancer symposium 2011, San Antonio, 6–10 Dec 2011
Zhang XH, Wang Q, Gerald W et al (2009) Latent bone metastasis in breast cancer tied to src-dependent survival signals. Cancer Cell 16(1):67–78
Perfitt AM (2002) Targeted and nontargeted bone remodeling: relationship to basic multicellular unit organization and progression. Bone 30(1):5–7
Xiong J, O’Brien CA (2012) Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res 27(3):499–505
Fu Q, Manolagas SC, O’Brien CA (2006) Parathyroid hormone controls receptor activator of NF-kB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol 26:6453–6468
Tsutsumi S, Ishii K, Amizuka N et al (2007) Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5:464–475
O’Flaherty (2000) Modeling normal aging bone loss, with consideration of bone loss in osteoporosis. Toxicol Sci 55(1):171–188
James JJ, Evans AJ, Pinder SE et al (2003) Bone metastases from breast carcinoma: histopathological -radiological correlations and prognostic features. Br J Cancer 89(4):660–665
Chen Z, Maricic M, Petinger M et al (2005) Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer: results from a subgroup in the women’s health initiative observational study. Cancer 104(7):1520–1530
Uenishi K (2011) Hone no eiyo (Bone nutrition). In: Ueno NT, Kono N, Nakamura S, Hayashi N (eds) Chiem de manabu nyugan no kotsu management (Team-based management of bone metastases in breast cancer), 1st edn. Shinoharashinsha, Tokyo
Yoon V, Maalouf NM, Sakhaee K (2012) The effects of smoking on bone metabolism. Osteoporosis Int 23(8):2081–2092
Mathot L, Stenninger J (2012) Behavior of seeds and soil in the mechanism of metastasis; a deeper understanding. Cancer Sci 103(4):626–631
Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revised. Nat Rev Cancer 3(6):453–458
Theriault RL, Theriault RL (2012) Biology of bone metastasis. Cancer Control 19(2):92–101
Rose AN, Siegel PM (2010) Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol 6(1):55–74
Muller A, Homey B, Soto H et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56
Kozlow W, Guise TA (2005) Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10:169–180
Coleman RE, Seaman JJ (2001) The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin Oncol 28:11
Chirgwin JM, Guise TA (2000) Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10(2):159–178
Chiang AC, Massagué J (2008) Molecular basis of metastasis. N Engl J Med 359(26):2814–2823
Guise TA (2002) The Vicious cycle of bone metastasis. J Musculoskel Neuron Interact 2(6):57–570
Hayashi N (2011) Hone teni no mechanism (Mechanism of bone metastases). In: Ueno NT, Kohno N, Nakamura S, Hayashi N (eds) Chiem de manabu nyugan no kotsu management (Team-based management of bone metastases in breast cancer), 1st edn. Shinoharashinsha, Tokyo
Simonet WS et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2):309–319
Roodman GD (2004) Mechanism of bone metastasis. N Engl J Med 350(16):1655–1664
Clines GA, Guise TA (2005) Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 12(3):549–583
Clevers H (2006) Wnt/β-catenin signaling in development and disease. Cell 127(3):469–480
Voorzanger-Rousselot N, Goehrig D, Journe F et al (2007) Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 97(7):964–970
Tian E, Zhan F, Walker R et al (2003) The role of the Wnt-signaling antagonist DDK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483–2494
Clézardin P (2011) Therapeutic targets for bone metastases in breast cancer. Breast Can Res 13(2):207
Yang X, Karsenty G (2002) Transcription factors in bone: developmental and pathological aspects. Trends Mol Med 8(7):340–345
Bing Y, Williams PJ, Niewolna M et al (2002) Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62(3):917–923
Valta MP, Hentunen T, Qu Q et al. (2006) Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology147(5):2171–2182
Dunn LK, Mohammad KS, Fournier PG et al (2009) Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE 4(9):e6896
Dai J, Keller J, Zhang J et al (2005) Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 65(18):8274–8285
Guise TA, Yin JJ, Mohammad KS (2003) Role of endothelin-1 in osteoblastic bone metastasis. Cancer 97(3 suppl):779–784
Clines GA, Mohammad KS, Bao Y et al. (2007) Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 21(2):486–498. Epub 2006 Oct 26
Yin JJ, Mohammad KS, Kakonen SM et al (2003) A casual model for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 100(19):10954–10959
Coleman RB (2000) Management of bone metastasis. Oncologist 5(6):463–470
Pagani O, Senkus E, Wood W (2010) International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 102(7):456–463
Hanrahan EO, Broglio ER, Buzdar AU et al (2005) Combined-modality treatment for isolated recurrence of breast carcinoma—update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer 104(6):1158–1171
Dürr HR, Müller PE, Lenz T et al (2002) Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res 396:191–196
Incarbone M, Nava M, Lequaglie C et al (1997) Sternal resection for primary or secondary tumors. J Thorac Cardiovasc Surg 114(1):93–99
Thompson RC (1992) Impeding fracture associated with bone destruction. Orthopedics 15(5):547–550
Harrington KD (1997) Orthopedic surgical management of skeletal complications of malignancy. Cancer 80(8):1614–1627
Tong D, Gillick L, Hendrickson FR (1982) The palliation of symptomatic osseous metastases: final results of the study by the radiation therapy oncology group. Cancer 50:893–899
Maranzano E, latini P (1995) Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys 32:959–967
Perez JE, Machiavelli M, Leone BA et al (1990) Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Group Oncologico Cooperativo del Sur. Am J Clin Oncol 13:294–298
Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19(10):2596–2606
Niikura N, Hayashi N, Palla S et al (2011) Treatment outcomes and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. Oncologist 16(2):155–164
Wong MH, Stockler MR, Palvakis N (2012) Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 15(2):CD003474
Diel IJ (2007) Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic disease: a review. Support Care Cancer 15(11):1243–1249. Epub 2007 Mar 29
Plunkett TA, Smith P, Rubens RD (2000) Risk of complications from bone metastases in breast cancer. Implications for management. Eur J Cancer 36(4):476–482
Schmid P, Possinger K (2003) Bisphosphonates in metastatic breast cancer. Breast Cancer Res Treat 81(suppl. 1):S87–S93
Petrut B, Trinkaus M, Simmons C et al (2008) A primer of bone metastases management in breast cancer patients. Curr Oncol 15(suppl 1):S50–S57
Iranikhah M, Wilborn TW, Wensel TM et al (2012) Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor. Pharmacotherapy 32(3):274–284
Barton MK (2011) Denosumab an option for patients with bone metastasis from breast cancer. CA Cancer J Clin 61(3):135–136
Fizazi K, Lipton A, Mariette X (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564–1571
Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastasis in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132–5139
Finlay IG, Mason MD, Shelley M (2005) Radioisotopes for the palliation of metastatic bone cancer: a systemic review. Lancet Oncol 6(6):392–400
Taira AV, Herfkens RJ, Gambhir SS et al (2007) Detection of bone metastases: assessment of integrated PDG PET/CT imaging. Radiology 243:204–211
Niikura N, Costelloe CM, Madewell JE et al (2011) PDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist 16:1111–1119
Carlson RW, Allred CA, Anderson BO et al (2011) Invasive breast cancer. J Natl Compr Cancer Net 9:136–222
Hamaoka T, Costelloe CM, Madewell JE et al (2010) Tumor response interpretation with new tumor response criteria vs the World Health Organization criteria in patients with bone-only metastatic breast cancer. Br J Cancer 102(4):651–657
Clines GA, Guise TA (2004) Mechanisms and treatment for bone metastases. Clin Adv Hematol Oncol 2(5):295–302
Onishi T, Hayashi N, Theriault R et al (2010) Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 7:641–651
Pickering LM, Mansi JL (2002) The role of bisphosphonates in breast cancer management: review article. Curr Med Res Opin 18(5):284–295
Britton KM, Kirby JA, Lennard TWJ et al (2011) Cancer stem cells and side population cells in breast cancer and metastasis. Cancers 3:2106–2130
Marchini C, Montani M, Konstantindou G et al (2010) Mesenchymal’stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. PLoS ONE 5(11):e14131
Zou W, Kitaura H, Reeve J et al (2007) Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol 176(6):877–888
Khalili P, Arakelian A, Chen G et al (2006) A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 5(9):2271–2280
Bretschi M, Merz M, Komljenovic D et al (2011) Cilengitide inhibits metastatic bone colonization in a nude rat model. Oncol Rep 26(4):843–851
Harms JF, Welch DR, Samant RS et al (2004) A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis 21(2):119–128
Rucci N, Recchia I, Angelucci A et al (2006) Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Ep Ther 318:161–172
Bakewell SJ, Nestor P, Prasad S (2003) Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci USA 100(24):14205–14210
Boyce BF, Yoneda T, Lowe C et al (1992) Requirement of pp 60c-serc expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 90:1622–1627
Saad F, Lipton A (2010) Src kinase inhibitor: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 36(2):177–184
Le Gall C, Bonnelye E, Clézardin P (2008) Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care 2:218–222
Le Gall C, Bellahcène A, Bonnelye E et al (2007) A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 67(20):9894–9902
Podgorski I (2009) Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis? Future Med Chem 1(1):21–34
Ramirez G, Jensen AB, Olmeo N et al. (2008) Effect of cathepsin K inhibition on supression of bone resorption in women with breast cancer and established bone metastases in a 4-week, double-blind, randomized controlled trial. Presented at breast cancer symposium 2008, Washington, 5–7 Sept 2008
Leto G (2010) Activin A and bone metastasis. J Cell Physiol 225(2):302–309
Leto G, Incorvaia L, Badalamenti G et al (2006) Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 23:117–122
Incorvaia L, Badalamenti G, Rini G et al. (2007) MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res 27(3B):1519–1525
Chantry AD, Heath D, Mulivor AW et al (2011) Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res 25(12):2633–2646
Mulivor AW, Barbosa D, Kumar R et al (2009) RAP-011, a soluble activin receptor type IIA murine IgG-Fc fusion protein, is a novel bone anabolic agent that prevents bone loss and skeletal loss in a mouse model of metastatic breast cancer. Bone 44(2):S221–S222
Tian E, Zhan F, Walker R et al (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483–2494
Grimshaw MJ, Hagemann T, Ayhan A et al (2004) A Role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res 64(7):2461–2468
Liao J, McCauley LK (2006) Skeletal metastasis: established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Met Rev 25:559–571
Lacey DL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176
Lyer S, Wang ZG, Akhtari M et al (2005) Targeting TGFβ signaling for cancer therapy. Cancer Biol Ther 4(3):261–266
Massague J (2008) TGFβ in cancer. Cell 134:215–230
Ye L, Mason MD, Jiang WG (2011) Bone morphogenetic protein and bone metastasis, implication and therapeutic potential. Front Biosci 1(16):865–897
Huang EH, Singh B, Cristofanilli M et al (2009) A XCXR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 155(2):231–236
Hassan S, Buchanan M, Jahan K et al (2011) CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 129(1):225–232
Wong D, Korz W (2008) Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer 14:7975–7980
Cabioglu N, Sahin AA, Morandi P et al (2009) Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 20(6):1013–1019. doi:10.1093/740
Henriksen G, Fisher DR, Roeske JC et al (2003) Targeting of osseous sites with alpha-emiting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med 44(2):252–259
Porta C (2012) The European multidisciplinary cancer congress (ECCO 16, ESMO 36 and ESTRO 30). Future Oncol 8(1):13–15
Nilsson S, Franzen L, Parker C et al (2007) Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomized, multicenter, placebo-controlled phase II study. Lancet Oncol 8(7):587–594
Coleman R, Flamen P, Naume B et al. (2011) An open-label, phase IIa, non-randomized study of radium-223 in breast cancer patients with bone dominant disease no longer considered suitable for endocrine therapy. Poster presentation at San Antonio breast cancer symposium 2011, San Antonio, 6–10 Dec 2011
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Brewer, T.M., Theriault, R.L., Ueno, N.T. (2013). Bone Metastasis of Breast Cancer. In: Ahmad, A. (eds) Breast Cancer Metastasis and Drug Resistance. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5647-6_11
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5647-6_11
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5646-9
Online ISBN: 978-1-4614-5647-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)